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Purpose
We aimed to assess prognostic value of metastatic pelvic lymph node (mPLN) in early-stage
cervical cancer treated with radical surgery followed by postoperative chemoradiotherapy.
Also, we sought to define a high-risk group using prognosticators for recurrence. 
Materials and Methods
A multicenter retrospective study was conducted using the data from 13 Korean institutions
from 2000 to 2010. A total of 249 IB-IIA patients with high-risk factors were included. We
evaluated distant metastasis-free survival (DMFS) and disease-free survival (DFS) in relation
to clinicopathologic factors including pN stage, number of mPLN, lymph node (LN) ratio (num-
ber of positive LN/number of harvested LN), and log odds of mPLNs (log(number of positive
LN+0.5/number of negative LN+0.5)).
Results
In univariate analysis, histology (squamous cell carcinoma [SqCC] vs. others), lymphovas-
cular invasion (LVI), number of mPLNs ( 3 vs. > 3), LN ratio ( 17% vs. > 17%), and log
odds of mPLNs ( 0.58 vs. > 0.58) were significant prognosticators for DMFS and DFS.
Resection margin involvement only affected DFS. No significant survival difference was ob-
served between pN0 patients and patients with 1-3 mPLNs. Multivariate analysis revealed
that mPLN > 3, LVI, and non-SqCC were unfavorable index for both DMFS (p < 0.001,
p=0.020, and p=0.031, respectively) and DFS (p < 0.001, p=0.017, and p=0.001, respec-
tively). A scoring system using these three factors predicts risk of recurrence with relatively
high concordance index (DMFS, 0.69; DFS, 0.71).
Conclusion
mPLN > 3 in early-stage cervical cancer affects DMFS and DFS. A scoring system using
mPLNs > 3, LVI, and non-SqCC could stratify risk groups of recurrence in surgically resected
early-stage cervix cancer with high-risk factors.
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Introduction
Cervical cancer is newly diagnosed in 3,500 patients in the
Korea in 2014 [1]. Despite a declining trend over the last 40
years, the incidence and mortality rate among young women
increased [2]. Since cancer screening using Pap smear has
been widely used, about three quarters of newly diagnosed
cases are the International Federation of Gynecology and 
Obstetrics (FIGO) stage I or IIA [3]. These early cervical can-
cer are subject to radical surgery and has a relatively favor-
able prognosis with a 5-year overall survival (OS) rate of 90%
and a disease-free survival (DFS) rate of 82% [4]. However,
pathologic findings including positive resection margin
(RM), parametrial (PM) involvement, and lymph node (LN)
metastasis are considered as high risk factors for recurrence
and patients with those factors are candidate for postopera-
tive chemoradiotherapy (CRT) [5]. Pelvic LN metastasis is
found in nearly half of cases, even in early stage cervical can-
cer [6] and in this setting, the 5-year relative survival rate was
57.4% [7]. In a Gynecologic Oncology Group (GOG) 49 study 
including FIGO IB patients, the 5-year DFS of patients with
metastatic pelvic LN (mPLN) was 10% lower than those
without [8]. In pooled analysis of GOG 24/56/59, LN metas-
tasis was statistically significant variable for both DFS (haz-
ard ratio [HR], 1.9) and OS (HR, 2.0) [9]. 
Several researchers have assessed prognostic meaning of
mPLN in various ways. The simplest is counting the number
of mPLN, which is intuitive and widely used in other cancers
[10,11]. The LN ratio (LNR) which has been developed to 
reflect the extent of LN resection and the log odds of positive
LN (LODDs) which has the advantage of reflecting the num-
ber of negative LNs are suggested as prognostic variables 
related to LN status [12]. However, those studies were lim-
ited in that most of them are single institutional retrospective
series and also, included heterogeneous population in terms
of tumor stages and treatment characteristics. Until now, it
is unclear that among several parameters related to LN sta-
tus, which one serves as a best prognostic factor.
We therefore aimed to assess prognostic value of the num-
ber of and related parameters of mPLN in patients with
early-stage cervical cancer treated with radical surgery fol-
lowed by postoperative CRT due to pathologic high risk fac-
tors. Also, we sought to find a high risk group of recurrence
in these patients.
Materials and Methods
1. Patient cohort 
We conducted a multicenter retrospective study (Korean
Radiation Oncology Group [KROG] 15-04) at affiliated 13 
institutions in South Korea. After the approval of Institu-
tional Review Board of each institution, medical records of
patients who were newly diagnosed of FIGO IB-IIA cervical
cancer between 2000 and 2010, and treated with radical sur-
gery followed by postoperative CRT due to pathologic high
risk features including positive RM, PM invasion, and LN
metastasis were reviewed. We intended to enroll homoge-
neous group of patients without clinically involved LN on
preoperative positron emission tomography/computed 
tomography (PET/CT) or magnetic resonance imaging
(MRI). This is because definitive CRT or radiotherapy (RT)
is often recommended in those with gross mPLNs which are
LNs with increased metabolism than the background
(PET/CT) or those with a short diameter greater than 1 cm
(MRI). Additionally, patients who received preoperative
chemotherapy (CTx), who did not receive radical surgery,
who have insufficient information on the extent of surgery
or pathologic report, who did not complete adjuvant CRT,
or who have with history of other malignancies were 
excluded. Finally, a total of 259 patients were candidates of
this study, and each institutional review board’s approval
was achieved. The patient selection process is depicted in 
S1 Fig. 
2. Treatment
All patients underwent radical hysterectomy with pelvic
LN dissection according to our inclusion criteria. Para-aortic
LN sampling or dissection was carried out in 120 patients
(46.3%). Postoperative RT was delivered to whole pelvis in
daily fraction of 1.8-2 Gy with median dose of 50.4 Gy (range,
41.4 to 60.4 Gy). Brachytherapy was performed in 36 patients
(18%) with median dose of 18 Gy (range, 5 to 28 Gy) follow-
ing whole pelvic RT. Nineteen patients (7.3%) underwent
para-aortic nodal irradiation with a median dose of 45 Gy
(range, 45 to 60 Gy), of whom nine patients received RT pro-
phylactically. Most of all patients (97.3%) received platinum-
based CTx during CRT. The most common CTx regimen was
weekly cisplatin (50.2%), and doublet of 5-fluorouracil and
cisplatin was the second (24.5%). 
3. Variables and statistical analysis
All patients were staged using 2009 FIGO staging system
[13]. As FIGO staging system does not describe presence of
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LN metastases, pathologic nodal status was described sepa-
rately as pN0 or pN1 based on seventh edition of American
Joint Committee on Cancer staging system [14]. Additionally,
we evaluated parameters related to LN status such as the
number of mPLNs, LNR, and LODDs. LNR was calculated
by dividing the number of mPLNs by the number of har-
vested LNs (Eq. 1). 
LNR= No. of mPLNs                                       (1)
No. of harvested LNs
LODDs was defined as the logarithm of odds ratio of neg-
ative LNs over positive LNs (Eq. 2) [12]. 
LODDs=log No. of mPLNs+0.5                       (2)
No. of negative LN+0.5
In this Eq. (2), 0.5 is added constant to avoid an infinite
number. Cutoff value of these parameters was determined
by maximal chi-square method. 
Distant metastasis-free survival (DMFS) was defined as an
interval between the surgery and the detection of distant
metastasis or last follow-up. DFS was calculated from the
surgery to the detection of any recurrence or last follow-up.
In-pelvic recurrences are regarded as locoregional failures
while para-aortic LN failures as distant. Survival curves were
estimated by Kaplan-Meier method and survival differences
were evaluated using log-rank test. Statistically significant
variables in univariate analyses were included in a step-wise
Cox proportional hazard regression model for multivariate
analyses. In the modeling process, variables with p < 0.20
were put into and those with p > 0.10 were eliminated from
the regression model. A p-values < 0.05 was considered sta-
tistically significant. All statistical analyses were performed
by R ver. 3.2.4 (R Foundation for Statistical Computing, 
Vienna, Austria, http://www.r-project.org). 
4. Ethical statement
The study was approved by the Institutional Review Board
of Seoul National University Bundang Hospital (IRB No. 
B-1511/324-109) and performed in accordance with the prin-
ciples of the Declaration of Helsinki. The informed consent
was waived. 
Results
1. Patient demographics 
The median age of patients was 47 years (range, 25 to 74
years) and about three-quarters of patients was FIGO stage
IB. The most common histology was squamous cell carci-
noma (SqCC; 71.8%) followed by adenocarcinoma (ADC;
18.5%). Deep stromal invasion greater than 1/2 thickness,
bulky tumor more than 4 cm, and lymphovascular invasion
(LVI) were found in 88.6%, 33.2%, and 78.9% of patients, 
respectively. Patients with PM extension or positive RM were
45.6% and 14.3%, respectively. Two hundred and seven 
patients (79.9%) were pN1. The median number of harvested
LNs and mPLNs were 26 (range, 4 to 85) and 1 (range, 0 to
19), respectively. Of 120 patients who underwent para-aortic
LN sampling or dissection, 10 patients (3.9%) had metastatic
para-aortic LNs. Thirty-six patients (13.9%) received a con-
solidative CTx following adjuvant CRT at the discretion of
treating physician. Patient demographics are summarized in
Table 1.
2. Survival analysis 
As the presence of para-aortic LN metastases is an obvious
poor prognostic factor for DMFS and DFS, 10 patients with
para-aortic LN metastases were excluded from subsequent
survival analyses to avoid possible confounding effect. Con-
sequently, 249 patients were included for survival analyses
of DMFS and DFS. Median follow-up duration was 70
months (range, 2.5 to 468.5 months). Five-year DMFS and
DFS of 249 patients were 83.5% and 78.1%, respectively. Dis-
tant failure occurred in 42 patients and crude distant failure
rate was 16.9%. The lungs were the most common site of fail-
ure (33.3%) and the second most common was para-aortic
LN (28.6%). Locoregional failure occurred in 23 patients
(9.2%) and there were 11 patients who experienced both 
locoregional and distant failure. 
Determined cutoff value for the number of mPLNs, LNR
and LODDs for DMFS were 3, 17%, and 0.58, respectively
(S2 Fig.). The proportion of patients with mPLNs  3, LNR 
 17%, and LODDs  0.58 were 81.1%, 86.0%, and 87.6%, 
respectively.  
In univariate analysis, non-SqCC (p=0.007), the presence
of LVI (p=0.021), mPLNs > 3 (p=0.018), pelvic LNR > 17%
(p=0.041), and LODDs > 0.58 (p=0.048) were significant
poor predictors for DMFS. However, no survival difference
was observed according to the number of harvested LNs
(p=0.121), duration of RT (p=0.282), or consolidative CTx
(p=0.536). As for DFS, the survival rate was significantly dif-
ferent according to following factors: non-SqCC (p < 0.001),
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presence of LVI (p=0.029), mPLNs > 3 (p=0.001), pelvic LNR
> 17% (p=0.016), and LODDs > 0.58 (p=0.014), and RM pos-
itivity (p=0.018), respectively. DFS was not influenced by the
number of harvested LNs (p=0.153), duration of RT
(p=0.975), or consolidative CTx (p=0.638). These results are
presented in Table 2. 
Interestingly, pathologic N stage itself was independently
associated with neither DMFS (p=0.910) nor DFS (p=0.839)
(Fig. 1A). As the cutoff value of mPLN determined by max-
imal chi-square test was 3, we compared survival differences
between three groups of patients: patients with pN0, patients
with 1-3 mPLNs, and patients with mPLNs more than 3. Sur-
vivals of patients with 1-3 mPLNs were significantly higher
(5-year DMFS, 86.0%; 5-year DFS, 82.7%) than those with 
> 3 mPLNs (5-year DMFS, 70.9%, p=0.017; 5-year DFS, 60.0%,
p=0.001). However, survival differences between patients
with pN0 and  3 mPLNs were not statistically significant 
(5-year DMFS, 87.7%, p=0.616; 5-year DFS, 81.6%, p=0.535).
Fig. 1B depicts survival curves according to these three
groups.
In multivariate analysis (Table 3), both DMFS and DFS
were significantly affected by three factors: non-SqCC histol-
ogy (DMFS: p=0.001; HR, 2.96 and DFS: p < 0.001; HR, 3.46),
LVI (DMFS: p=0.020; HR, 4.08 and DFS: p=0.017; HR, 3.10),
and mPLNs > 3 (DMFS: p=0.031; HR, 2.08 and DFS: p=0.001;
HR, 2.65). S3 Fig. shows survival curves according to these
factors. Other LN-related parameters (pN stage, LNR, or
LODDs) lost their significance after adjusting interaction 
between variables. 
3. A scoring system for prediction of DMFS and DFS
A scoring system was built based on the results of multi-
variate analysis (Table 4). Non-SqCC histology, presence of
LVI, and mPLNs > 3 were counted independently as 1 point
with total score ranging from 0 to 3. As a result, patients were
stratified into four groups as follows: 28 patients (12.1%) with
score 0, 125 patients (53.9%) with score 1, 69 patients (29.7%)
with score 2, and 10 patients (4.3%) with score 3, respectively.
The 5-year DMFS and DFS were 100% in patients with score
Table 1. Patient and tumor characteristics
Characteristic No. (%)
Age at diagnosis, median (range, yr) 47 (25-74)
FIGO stage
IB 202 (78.0)
IIA 57 (22.0)
Histology
Squamous cell carcinoma 186 (71.8)
Adenocarcinoma 48 (18.5)
Adenosquamous carcinoma 11 (4.3)
Mucinous adenocarcinoma 4 (1.5)
Small cell carcinoma 3 (1.2)
Others 7 (2.7)
Deep stromal invasion (%)a)
 50 28 (11.4)
> 50 218 (88.6)
Bulky tumor (cm)a)
 4 163 (66.8)
> 4 81 (33.2)
Lymphovascular  invasiona)
Negative 51 (21.1)
Positive 191 (78.9)
Parametrial extension
Negative 141 (54.4)
Positive 118 (45.6)
Resection margin
Negative 222 (85.7)
Positive 37 (14.3)
Pathologic N stage
N0 52 (20.1)
N1 207 (79.9)
No. of harvested pelvic LNs
Median (range) 26 (4-85)
 25 125 (48.3)
> 25 134 (51.7)
No. of metastatic pelvic LNs
Median (range) 1 (0-19)
0 52 (20.1)
1 88 (34.0)
2 44 (17.0)
 3 75 (29.0)
Para-aortic LN dissection
Not done 139 (53.7)
Done 120 (46.3)
Para-aortic LN metastasis
Absent 110 (91.7)
Present 10 (8.3)
Duration of radiotherapy (wk)
 7 199 (76.8)
> 7 60 (23.2)
Consolidative chemotherapy
Not done 223 (86.1)
Done 36 (13.9)
Table 1. Continued
FIGO, International Federation of Gynecology and Obstet-
rics; LN, lymph node. a)Available cases analysis. 
Characteristic No. (%)
High-risk factor
1 168 (64.9)
2 79 (30.5)
3 12 (4.6)
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(Continued)
Characteristic DMFS DFS
5-Year (%) p-valuea) 5-Year (%) p-valuea)
5-Year overall probability 83.5 78.1
Age (yr)
 50 83.2 0.860 77.2 0.732
> 50 84.0 79.4
FIGO stage
IB 81.6 0.373 77.2 0.554
IIA 90.6 81.8
Histology
SqCC 87.7 0.007 84.1 < 0.001
Others 72.5 63.0
Deep stromal invasion
 50% 92.2 0.183 88.7 0.196
> 50% 83.0 78.1
Bulky tumor (cm)
 4 84.5 0.602 80.8 0.482
> 4 83.7 77.0
Lymphovascular invasion
Negative 93.7 0.021 90.6 0.029
Positive 80.3 75.1
Parametrial invasion
Negative 85.3 0.290 78.7 0.803
Positive 81.3 77.2
Resection margin
Negative 84.3 0.322 80.9 0.018
Positive 78.5 61.4
Pathologic N stage
N0 87.8 0.910 81.6 0.839
N1 82.5 77.4
No. of metastatic LNs
 3 86.4 0.018 82.3 0.001
> 3 70.9 60.0
Pelvic LNR (%)
 17 85.7 0.041 80.8 0.016
> 17 69.8 61.8
LODDs
 –0.58 85.5 0.048 80.7 0.014
> –0.58 69.1 60.0
No. of harvested LNs
 25 79.0 0.121 73.3 0.153
> 25 88.0 83.0
Duration of radiotherapy (wk)
 7 85.2 0.282 78.3 0.975
> 7 77.3 77.3
Consolidative chemotherapy
Not done 82.4 0.536 76.7 0.638
Done 84.9 78.8
Table 2. Univariate survival analysis for DMFS and DFS 
DMFS, distant metastasis-free survival; DFS, disease-free survival; FIGO, International Federation of Gynecology and 
Obstetrics; SqCC, squamous cell carcinoma; LN, lymph node; LNR, lymph node ratio; LODDs, log odds of positive lymph
nodes. a)p-value by log-rank test.
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0. In contrast, 5-year DMFS and DFS were 50% and 40% in
patients with score 3. In patients with score 1 and 2, 5-year
DMFS and DFS were 88.6%/71.2% and 85.9%/62.1%, respec-
tively (Fig. 2). The Harrell's C index of the scoring system for
DMFS and DFS were 0.69 and 0.71. 
Additionally, we developed prognostic nomogram for DFS
using above three risk factors to specifically estimate indi-
vidual patient’s prognosis (Fig. 3A, Supplementary Method).
The nomogram suggested that non-SqCC histology had the
largest impact on prognosis. The concordance index of our
nomogram predicting 5-year survival probability was 0.69.
The calibration plot depicted a good correspondence 
between the nomogram-predicted survival and actuarial sur-
vival rate at 5 years (Fig. 3B). 
Discussion
The present study enrolled homogenous groups of patients
diagnosed of FIGO IB-IIA cervical cancer without clinically
Fig. 1.  Distant metastasis-free survival (DMFS) and disease-free survival (DFS) curves according to pN stage (A), and
number of metastatic pelvic lymph nodes (LNs) (B).
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involved LNs, treated by radical surgery and adjuvant CRT
owing to postoperative high risk features. This study demon-
strates that the number of mPLN shows best prognostic per-
formance among parameters related to LN status. DMFS and
DFS of patients with mPLN  3 did not differ from those with
pN0. In contrast, the risk of recurrence in patients with
mPLNs > 3 remained high even though postoperative CRT
was performed. Additionally, we proposed a scoring system
which can discriminate poor prognostic group of patients
using three factors including tumor histology, LVI, and the
number of mPLN. It is simple and correlates well with DMFS
and DFS.
Characteristic DMFS DFS
HR (95% CI) p-valuea) HR (95% CI) p-valuea)
Histology
SqCC 1 ( 0.001 1 ( < 0.001
Others 2.96 (1.58-5.56) 3.46 (1.97-6.07)
Lymphovascular invasion
Negative 1 ( 0.020 1 ( 0.017
Positive 4.08 (1.25-13.34) 3.10 (1.22-7.87)
No. of metastatic LNs
 3 1 ( 0.031 1 ( 0.001
> 3 2.08 (1.07-4.04) 2.65 (1.48-4.75)
Table 3. Multivariate analysis for DMFS and DFS
DMFS, distant metastasis-free survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; SqCC, squamous
cell carcinoma; LN, lymph node. a)p-value by Cox proportional hazard model with backward stepwise regression.
Fig. 2.  Distant metastasis-free survival (DMFS) (A) and disease-free survival (DFS) (B) curves according to the scoring system.
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Table 4. A scoring system for prediction of distant failure
SqCC, squamous cell carcinoma; LN, lymph node. 
Characteristic 0 1
Histology SqCC Others
Lymphovascular invasion Negative Positive
No. of metastatic LNs  3 > 3
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Some of well-known prognosticators such as bulky tumor
size, deep stromal invasion, positive RM, and PM involve-
ment for early cervical cancers did not affect survivals in the
present study. As those factors are mainly derived from sur-
gical series to establish indications of adjuvant treatment
[8,15,16], proper prognostic factors in early cervical cancers
with high risk features are currently unknown when stan-
dard treatment including radical surgery and postoperative
CRT were performed. Our findings suggest that prognosti-
cators for survivals in this specific setting would be different
from those in surgical series and should be defined sepa-
rately.
The LN status affects prognosis of patients and several 
parameters associated with LN status were suggested in the
previous studies. It is agreed that pN1 disease is a heteroge-
neous group in terms of the location and the tumor burden
of involved LN. Nodal staging system based on the number
of metastatic LNs is widely used in other cancers of breast,
stomach, and rectum [14]. In studies of patients with early
stage cervical cancer treated with radical surgery followed
by RT, some authors showed that the survival difference of
patients between with one mPLN and  2 was statistically
significant [7,15]. KROG1303 study showed that the hazard
of death increases continuously with the number of mPLNs
(up to 5) [11]. On the other hand, Tsai et al. [10] reported that
patients with only one mPLN had achieved similar outcomes
compared to those with pN0 (5-year DFS, 84% vs. 87%;
p=0.48), and patients with  2 mPLNs had lower survival
rates (87% vs. 61%, p < 0.001) than those with pN0. In the
present study, there was no significant difference in survival
between patients with pN0 and those with 1-3 mPLNs which
is higher cut-off value than Tsai et al. [10]. The main differ-
ence between two is that whether concomitant CTx was 
administered or not. Possible explanation of the observed
difference in the number of significant mPLN will be that the
risk of recurrence, especially distant failure, might be atten-
uated by concomitant CTx in patients with 2-3 mPLNs.
The number of mPLNs directly depends on the extent of
LN dissection. Inadequate LN dissection results in underes-
timation of LN metastasis. The prognostic advantage of LNR
as a surrogate for LN status, which reflects the number of
mPLN as well as the degree of LN dissection, has been rec-
ognized. Fleming et al. [17] reported decreased survivals in
patients with high LNR (6.6% for progression-free survival,
and 7.6% for OS) compared to those with low LNR in early
stage cervix cancer. Li et al. [18] and Polterauer et al. [19]
showed that the prognosis of patients with high LNR greater
than 10% was poor. The present study suggests a cutoff value
of 17% for LNR. As the median number of harvested LNs
was 26 in the current study, which is not much different from
the previous studies (Fleming et al. [17], median 19; Chen et
al. [20], median 26), relatively high LNR cutoff in our study
may be attributed to the improved survival of patients with
pN1 in our study. The 5-year OS of pN1 patients in the pres-
ent study was 84.9% which is higher than 22.4% (OS) in Chen
et al. [20]. Additionally, Fleming et al. [17] reported a 5-year
PFS of around 67% in patients with > LNR 6.6%, which is
similar to those with LNR > 16% in our study (68.3%). More
recently, Li et al. [18] and Zhou et al. [21] suggested cutoff
values of LNR as 20% and 17% which is consistent with our
Fig. 3. Nomogram predicting disease-free survival (DFS) (A) and calibration plot (B). SqCC, squamous cell carcinoma. 
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results.
LODDs reflects not only the extent of LN dissection, but
also negative LNs. It has the advantage of further discrimi-
nating patients with LNR close to zero or one [22]. For exam-
ple, if the number of mPLN is zero, the LNR will be zero 
regardless of the dissection extent, but the LODDs will vary 
depending on the number of negative LNs (S4 Fig.). It has
been studied actively in rectal and gastric cancers, but not in
cervical cancers. Kwon et al. [12] reported the prognostic 
superiority of LODDs to the number of mPLNs and LNR in
a patient group similar to our study, but it was limited due
to small number of patients. In the present study, LODDs
was a significant prognostic factor in univariate analysis, but
lost its significance in multivariate analysis. In order for
LODDs to acquire superior predictability, the number of neg-
ative LNs should be different among patients with mPLNs
 3 with or without recurrences, but there was no significant
difference (t test, p=0.458 for distant recurrence, p=0.2488 for
overall recurrence).
In addition to the number of mPLN, our study revealed
that LVI and histologic type were meaningful factors for pre-
dicting DFS as well as DMFS. The prognostic significance of
LVI has been reported in many studies including GOG 49 [8]
and is still an important prognosticator even after adjuvant
RT [23]. In addition, LVI has been reported to be significantly
associated with pelvic LN metastasis in stage IB cervical can-
cer [24]. Similarly, LVI was associated with mPLN (chi-
square test, p=0.002) in our study, but it was an independent
prognostic factor for both DMFS and DFS after adjusting 
interaction between two variables. These are in line with pre-
vious studies.
ADC in cervix cancer has been considered to have biolog-
ical aggressiveness and to be more resistant to adjuvant treat-
ment [25,26]. In the present study, ADC histology carried a
poor prognosis with 71.8% of DMFS and 61.8% of DFS at 
5 years compared to SqCC with 87.7% of DMFS and 84.1%
of DFS at 5 years, respectively. The significantly lower sur-
vivals of ADC are consistent with the findings of Hosaka et
al. [25] and Galic et al. [27]. In the study of Intaraphet et al.
[28], the risk of cancer-related death was significantly higher
in patients with small cell neuroendocrine carcinoma or ADC
than those with SqCC. Of note, an unfavorable prognosis of
ADC was observed only in advanced stages while there was
no significant survival difference in early stages [28]. More
recently, Winer et al. [29] also reported that equivalent sur-
vival outcomes regardless of histologic type were achieved
in patients with early stage cervix cancer. The discrepancies
between studies may be explained by the difference of 
patient characteristics: all patients in our study have early
stages, but belong to the high-risk group. It could be sup-
ported by the study of Mabuchi et al. [30] showing that ADC
was an independent poor prognostic factor for survivals in
intermediate- and high-risk group, but not in low-risk group
of patients with early cervical cancer. 
Our study is limited inherently by its retrospective nature:
the data were collected from 13 institutions in a retrospective
manner. It resulted in the following weakness: data on the
performance status of patients, pretreatment anemia, trans-
fusion, and treatment-related toxicities were missing and 
unable to analyze. In addition, favorable treatment outcomes
of our study may suggest a potential selection bias. However,
to the best of our knowledge, the present study is the largest
study focusing on early cervical cancer patients without clin-
ical LN involvement carrying high-risk factors who under-
went radical surgery followed by adjuvant CRT. For this
specific patient population, our study suggested three prog-
nostic factors including histologic type, LVI, and the number
of mPLN for DMFS and DFS, and provides simple scoring
system for predicting DMFS and DFS. It is worthwhile to
identify patient groups at risk of treatment failure despite
adjuvant CRT. 
In conclusion, the risk of recurrence, especially distant fail-
ure, remains high when adjuvant CRT is performed in 
patients with mPLNs > 3. New prognostic scoring system
consisted of mPLNs > 3, presence of LVI and non-SqCC is
suggested, and it could stratify patients according to risk of
recurrence in early cervix cancer with high-risk factors. Fur-
ther treatment options such as consolidative CTx after adju-
vant CRT should be considered to improve treatment
outcomes in patients having poor prognostic factors and
prospective trials are warranted.
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